Acute impact of inhaled short acting b2-agonists on 5 km running performance.

نویسندگان

  • John Dickinson
  • Jiu Hu
  • Neil Chester
  • Mike Loosemore
  • Greg Whyte
چکیده

Whilst there appears to be no ergogenic effect from inhaled salbutamol no study has investigated the impact of the acute inhalation of 1600 µg, the World Anti-Doping Agency (WADA) daily upper limit, on endurance running performance. To investigate the ergogenic effect of an acute inhalation of short acting β2-agonists at doses up to 1600 µg on 5 km time trial performance and resultant urine concentration. Seven male non-asthmatic runners (mean ± SD; age 22.4 ± 4.3 years; height 1.80 ± 0.07 m; body mass 76.6 ± 8.6 kg) provided written informed consent. Participants completed six 5 km time-trials on separate days (three at 18 °C and three at 30 °C). Fifteen minutes prior to the initiation of each 5 km time-trial participants inhaled: placebo (PLA), 800 µg salbutamol (SAL800) or 1600 µg salbutamol (SAL1600). During each 5 km time-trial HR, VO2, VCO2, VE, RPE and blood lactate were measured. Urine samples (90 ml) were collected between 30-180 minutes post 5 km time-trial and analysed for salbutamol concentration. There was no significant difference in total 5 km time between treatments (PLA 1714.7 ± 186.2 s; SAL800 1683.3 ± 179.7 s; SAL1600 1683.6 ± 190.7 s). Post 5 km time-trial salbutamol urine concentration between SAL800 (122.96 ± 69.22 ug·ml(-1)) and SAL1600 (574.06 ± 448.17 ug·ml(-1)) were not significantly different. There was no improvement in 5 km time-trial performance following the inhalation of up to 1600 µg of salbutamol in non-asthmatic athletes. This would suggest that the current WADA guidelines, which allow athletes to inhale up to 1600 µg per day, is sufficient to avoid pharmaceutical induced performance enhancement. Key pointsInhaling up to 1600 µg of Salbutamol does not result in improved 5 km time trial performance.The position of Salbutamol on the World Anti-Doping Agency list of prohibited appears justified.Athletes who use up to 1600 µg Salbutamol in one day need to review their therapy as it would suggest their respiratory condition is not under control.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Review: regular inhaled short-acting beta2-agonists improve lung function in stable chronic obstructive pulmonary disease.

Ram FS, Sestini P. Regular inhaled short acting b2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003;58:580–4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....

متن کامل

Excess mortality in patients with asthma on long-acting beta2-agonists.

A sthma ranks among the most common of chronic diseases in the Western world. Although modern therapy has improved patient care, asthma still affects 5–10% of the population and, according to the World Health Organization, claims the lives of some 12,000 patients per year in Western Europe [1]. b2-Agonists are potent bronchodilators and are the most widely prescribed drugs for asthma worldwide....

متن کامل

Inhaled Long-Acting fl2-Agonists in the Treatment of Asthma?*

treatment guidelines agree that they are the agents of choice to relieve bronchoconstriction in acute asthma.1'2 There has been considerable debate, however, as to the therapeutic value of regular inhaled shortacting 02-agonists long term.3'4 Particularly at issue is the concern that they may have the potential to worsen asthma control, thereby contributing to an increase in asthma mortality ob...

متن کامل

Drugs 2009;

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2363 1. Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2365 2. Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . ...

متن کامل

Evaluation of asthma control by inhaled corticosteroids in general practice in Thailand.

BACKGROUND Inhaled corticosteroid (ICS) is the main treatment of asthma but the clinical data of its efficacy is limited. This study aimed to evaluate the therapeutic efficacy of ICS alone or combined with controllers other than LABA for persistent asthma in Thailand. METHODS This cross-sectional study involved 1,206 patients with persistent asthma and was conducted at 38 hospitals across Tha...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of sports science & medicine

دوره 13 2  شماره 

صفحات  -

تاریخ انتشار 2014